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Experiência portuguesa com Nivolumab no Programa de Acesso Precoce (PAP) em doentes com Cancro do Pulmão de Células Não Pequenas (CPCNP) previamente tratado
Resumo Objectivo: Avaliar a eficácia e o perfil de segurança do Nivolumab, um anticorpo inibidor dos checkpoints imunológicos, em doentes com cancro do pulmão de células não pequenas (CPCNP) metastizado, previamente tratado, na prática clínica diária. Métodos: Estudo retrospectivo multicêntrico, de doentes com CPCNP incluídos no Programa de Acesso Precoce (PAP) do Nivolumab. Os critérios de inclusão eram CPCNP histologicamente ou Introduction Worldwide, lung cancer is the leading cause of cancerrelated mortality among both men and women, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers, divided into non-squamous (70%) and squamous (30%) histologic subtypes. 1 Patients with locally advanced and metastatic NSCLC have poor prognosis, with a 5-year survival rate <5%. 2 Since the end of the 90 s, chemotherapy has been the initial standardof-care for patients with advanced NSCLC whose tumours do not harbour mutations sensitive to targeted therapies. The therapeutic landscape of NSCLChas shown great progress in recent years with the advent of immunecheckpoints inhibitors, leading to a significant improvement in patient life expectancy. These drugs modified the treatment standards, but data documenting real life experience are scarce. Nivolumab is a human IgG4 PD-1 immunecheckpoint-inhibitor antibody that blocks the interaction between PD-1 protein and its ligands PD-L1 and PD-L2, 3 which inhibits the immune response by limiting T cell proliferation and cytokine production. 4 Nivolumab was the first checkpoint inhibitor to show a survival benefit in previously treated advanced squamous and non-squamous NSCLC, compared to docetaxel in two randomized trials, CheckMate 017 5 and CheckMate 057. 6 Nivolumab showed a significantly longer overall survival (OS) and a favourable safety profile in patients experiencing disease progression during or after platinum-based chemotherapy. Median OS was 9.2 months compared with 6.0 months in squamous NSCLC (Check-Mate 017) 5 and 12.2 months compared with 9.4 months in non-squamous NSCLC (CheckMate 057). 6 Data on clinical effectiveness and safety of nivolumab in patients with poor performance status (PS) and in those with 70 years of age or older are scarce, 7---12 because such patients are usually excluded from randomized clinical trials. Three studies that included these patient subgroups, CheckMate 153, 13 CheckMate 169 14 and CheckMate 171 15 provided evidence that nivolumab tolerability is similar in all patient groups and that effectiveness is comparable in all age groups, but that patients with an Eastern Cooperative Oncology Group (ECOG) PS of 2 experience shorter OS.
The Portuguese Nivolumab expanded access programme (EAP) in advanced NSCLC provided an opportunity for patients to gain access to treatment during pharmacoeconomical evaluation. In contrast to the inclusion criteria in controlled clinical trials, the eligibility criteria for the EAP were very broad, allowing the investigators to prescribe the use of nivolumab in a setting comparable to clinical practice. We present an analysis of the efficacy and safety of nivolumab in patients with advanced NSCLC enrolled in the EAP in Portugal. The main aim of this study is to analyse the characteristics, the treatment outcomes and safety of patients with advanced stage NSCLC treated with nivolumab in second or further lines in our clinical practice and correlate the results with clinical trial outcomes. Moreover, a secondary aim is to perform subgroup analysis in order to identify predictive biomarkers.
Methods

Patients
The EAP population comprised patients aged ≥18 years with histologically or citologically confirmed stage IIIB or IV NSCLC (squamous and non-squamous) that had progressed or recurred after at least one prior systemic treatment for advanced or metastatic disease. Patients were required to have an ECOG Performance Status of 0, 1 or 2; completion of prior chemotherapy, tyrosine kinase inhibitors or palliative radiotherapy, 2 weeks before starting nivolumab; resolution of all adverse events (AEs) to grade 1 (NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events, version 4) at baseline; adequate organ function and a life expectancy of at least 6 weeks. Exclusion criteria included active brain metastasis, positive test for hepatitis B or C virus indicating acute or chronic infection, known history of testing positive for human immunodeficiency virus (HIV), a severe autoimmune disease and patients with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisolone equivalent) or other immunosuppressive medications.
The treatment plan was explained in detail and all patients signed and dated a written informed consent form provided by Bristol-Myers Squibb. The study was approved by the INFARMED (Portuguese National Authority of Medicines and Health Products) and was executed in accordance with the Declaration of Helsinki, Good Clinical Practice, and local ethical and legal requirements.
Study design and treatment
We retrospectively collected clinical data for the eligible patients enrolled in the Nivolumab EAP at 30 Portuguese cancer centres from June 2015 to December 2016. All patients included were followed until the end of data collection on July 2018. The evaluation included a review of demographic and tumour characteristics: age, gender, smoking status, performance status, clinical stage, histology and number of previous treatments. All patients included in the analysis received at least one cycle of nivolumab at the standard dose of 3 mg per kilogram of body weight (60-minute intravenous infusion) every 2 weeks for ≤24 months. The treatment was continued depending on disease progression, unacceptable toxicity, completion of permitted cycles (24 months) or withdrawal of consent. Dose escalation or reduction was not allowed, but treatment could be delayed in the event of toxicity. Treatment beyond progression was allowed if, in the investigator's opinion, the patient was deriving clinical benefit, in the absence of rapid disease progression, severe toxicity or performance status escalation. Computed tomography (CT) based evaluation was performed around every 12 weeks.
Assessments
Demographic analysis included all patients in EAP. Safety was monitored by AE assessment, physical examination and laboratory tests. Investigators graded AEs according to the NCI CTCAE, version 4, and determined their causal relationship to treatment; for specific immune-related AEs, the protocol specific treatment guidelines were used. The EAP had no pre-specified end-points. Safety analysis included all patients treated (those who received at least one dose of study drug). Collected efficacy data included investigatorassessed objective tumour response, date of progression and survival information. Tumour response was assessed using the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1. Efficacy analysis included all evaluable patients and the exploratory assessments analysed were: Overall response rate (ORR; defined as the combined rates of complete and partial responses), disease control rate (DCR; defined as the combined rates of complete response, partial response and stable disease), progression-free survival (PFS) and overall survival (OS). PFS was defined as the time from date of first nivolumab treatment until date of first evidence of disease progression or death (whichever occurred first). The OS was also calculated from the first day of administration of nivolumab treatment until the patient's death or last date of follow-up.
Statistical analysis
A descriptive statistical analysis was performed, including central tendency and dispersion parameters for the quantitative variables and absolute and relative frequencies for categorical variables. Categorical variables were presented by numbers and percentiles, medians and ranges were reported for continuous variables. The Kaplan-Meyer method with a 95% Confidence Interval (CI) was used to estimate PFS and OS. Patients who were alive, without disease progression were censored at the time of last followup. Patients lost to follow-up were censored at the time of last contact. Patients who died because of their lung cancer before any radiological response evaluation were considered to have progressive disease at the time of death. A univariate analysis to test for differences between groups was performed using the log-rank test, followed by a multivariate analysis by Cox regression model to identify prognostic factors associated with OS. Univariate and multivariate hazard ratios were reported with a 95% CI. Statistical significance was set at p less than 0.05. All statistical analyses were carried out with SPSS Statistical Software, version 21.0 (IBM SPSS). We used BiostatXL MIX 2.0 (available at: http://www.meta-analysis-made-easy.com) to compute sub-group analysis estimates.
Results
Demographic and tumour characteristics and treatment
From June 2015 to December 2016, a total of 229 patients with advanced NSCLC were enrolled at 30 Portuguese centres. Of the 229 patients, data was available for analysis in 219 patients (3 patients did not start treatment, and unavailable data in 7 patients); all patients included in the analysis received at least one cycle of nivolumab. The median number of nivolumab cycles administered was 14 (range, 1---52). The median age at the start of the treatment was 64 years Total events (n = 28; 16.0%) ( Fig. 1 ). The 6, 12-and 18-month OS rates were 71%, 56.5% and 43% respectively.
Safety
Of the 178 patients (81.3%) who discontinued treatment, the reasons for discontinuation were progressive disease in 116 patients (52.2%), death in 23 patients (10.5%), adverse events in 28 (12.5%) and other reason in 22 (10%). A total of 136 patients had at least one adverse event in a total of 175 treatment---related AE's of any grade, among which 28 led to treatment discontinuation, listed in Table 2 . The most common toxicities reported were asthenia/fatigue, 41 events (23.4%), and endocrinopathy, 25 events (14.3%). Discontinuation of the study drug due to treatment-related AEs occurred in 28 patients (16%) in total, 10 of them (5.7%) due to pneumonitis and 6 (3.4%) due to colitis. AEs were managed using protocol-defined toxicity management algorithms.
Subgroup analysis
Subgroup analyses were performed for OS (Fig. 2) . In the univariate analysis, ECOG PS score was the only factor which significantly correlated with overall survival ( Fig. 2A ) by comparing patients who had an ECOG PS of 0---1 with those with an ECOG PS of 2, with a Hazard Ratio (HR) of 3.80 (95%CI: 2.30 to 6.07), p < 0.0001). There were no statistically significant differences in gender (p = 0.320), age (patients ≥75 vs. <75 years; p = 0.821), histology (squamous vs. non-squamous, p = 0.14), or number of prior therapy lines (≥2 vs. 1, p = 0.15) and smoking status (never vs. former/smoker, p = 0.43). In the multivariate analysis, ECOG PS score remained the only factor significantly related to overall survival (p < 0.0006). PS 0-1, Stage IIIB and Disease Control (DC) with nivolumab increase the probability of surviving at least one year, unlike PS 2 and Stage IV (Fig. 2B ).
Discussion
In our real-world population, median OS was 6.9 months (95% CI, 3.6---10.2) and 13.8 months (95% CI, 10.8---16.9) in squamous and non-squamous cell histological subtype, 13 efficacy and safety of nivolumab in older patients and patients with PS 2 has already been reported, nivolumab was effective and well tolerated in PS 2 patients, with no new safety concerns and a median OS of 3.9 months (95% CI, 3.1---6.3) and 1 year OS rate of 23% (95% CI, 16---32). Importantly, in our series, no negative correlation between the patients' age and OS was demonstrated implying that elderly with good ECOG PS derive the same benefit from nivolumab as their younger counterparts. These findings are in accordance with the results of CheckMate 057, 6 demonstrating similar benefit across all age subgroups that exist in real world.
Overall, nivolumab was well tolerated, with a favourable AE profile and observed AEs consistent with those previously reported. Among registered adverse events, grades were very seldom documented except those leading to treatment discontinuation.
Conclusion
We have shown a clinically meaningful survival benefit in nivolumab treated patients, with a favourable safety profile. These clinically relevant data support the use of nivolumab as a treatment option for previously treated advanced NSCLC patients.
